Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Progression of disease within 24 months is a novel determinant of prognosis in patients with Waldenström macroglobulinemia who have received frontline fixed-duration induction therapy with bendamustine-rituximab.”
Title: POD24 is a Novel Determinant of Prognosis in Patients with Waldenström Macroglobulinemia
Authors: Saurabh Zanwar, Jithma P. Abeykoon, Shirley D’Sa, Damien Roos-Weil, Dirk R. Larson, Colin L. Colby, Eric Durot, Efstathios Kastritis, Encarl Uppal, Oliver Tomkins, Pierre Morel, Patrizia Mondello, Lydia Montes, Jonas Paludo, Sikander Ailawadhi, Shayna Sarosiek, Olabisi Ogunbiyi, Pascalle Cornillet-Lefebvre, S Vincent Rajkumar, Anne Quinquenel, Angela Dispenzieri, Rafael Fonseca, Morie A Gertz, Shaji K Kumar, Meletios Athanasios Dimopoulos, Stephen M. Ansell, Steven P. Treon, Jorge J. Castillo, Prashant Kapoor
You can read the Full Article in Blood Advances.
You can find more posts featuring Robert Orlowski on OncoDaily.
